지질대사이상증 치료제 시장 - 세계 시장 규모, 점유율, 동향 분석, 기회, 예측 보고서(2019-2029년)

Global Lipid Metabolism Disease Drug Market Size Expands at Significant CAGR of 7.1% to Reach USD 24.44 Billion by 2029.

Global lipid metabolism disease drug market is flourishing because of an increasing focus on the treatment of growing prevalence of lipid metabolism diseases driven by unhealthy lifestyle among people across the regions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Lipid Metabolism Disease Drug Market size at USD 16.19 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Global Lipid Metabolism Disease Drug Market size to grow at a significant CAGR of 7.1% reaching a value of USD 24.44 billion by 2029. Major growth drivers for the Global Lipid Metabolism Disease Drug Market include a rising demand for these drugs in various applications, including hospitals and retail pharmacies globally. The Global Lipid Metabolism Disease Drug Market comprises diverse entities, such as companies, proprietorships, and collaborations, committed to developing and distributing medications addressing a range of conditions within metabolic disorders. This involves producing insulin, pramlintide, and other diabetes drugs, along with anti-thyroid medications for hyperthyroidism. The Global Lipid Metabolism Disease Drug Market also encompasses medications for disorders in the pituitary, adrenal, and parathyroid glands, including segments for anti-diabetic and anti-thyroid drugs targeting metabolic diseases like hyperparathyroidism and hypopituitarism. However, the market's historical trajectory is marked by strict regulations from governmental bodies and national governments, leading to criticisms of high treatment costs. Sales challenges have emerged due to obligations to offer medications to public healthcare institutions and physicians at discounted rates, leading to reduced profit margins and impacting the market's overall expansion.

Impact of Geopolitical Tensions on the Global Lipid Metabolism Disease Drug Market

The Global Lipid Metabolism Disease Drug Market has been significantly impacted by intensifying geopolitical tensions in recent times. For instance, the ongoing Russia's war on Ukraine has disrupted supply chains and hindered the production and distribution of pharmaceuticals, affecting the availability of lipid metabolism disease drugs. In addition, the sanctions imposed on Russia by the United States and other countries can limit the movement of essential medical resources, leading to potential shortages. The turmoil has far-reaching consequences on healthcare measures in Ukraine and across the regions, exacerbating the demand for medicines, depleting inventories, and creating logistical obstacles for resupplying critical medical resources. Meanwhile, calls for economic disengagement from Russia by pharmaceutical industry leaders may affect investments and influence healthcare budgets, ultimately affecting patient affordability and the demand for lipid metabolism disease drugs. Beyond the conflict in Ukraine, collaborative research efforts and international partnerships vital for drug development may face strain, potentially slowing down innovations in the field. In essence, these geopolitical tensions introduce uncertainties and challenges across various dimensions of the lipid metabolism disease drug market, emphasizing the need for strategic adaptation and resilience in navigating these complex circumstances.

Despite the current challenges posed by geopolitical tensions, there are potential growth opportunities for the global lipid metabolism disease drug market. The heightened awareness of the vulnerabilities in the pharmaceutical supply chain due to escalating and spreading geopolitical tensions could drive industry stakeholders to invest in more resilient and diversified supply chain models. Innovations in telehealth and digital health solutions may emerge as a response to disruptions in traditional healthcare delivery systems, providing new avenues for patient access and engagement. Also, an increased focus on R&D to address the unique health challenges arising from geopolitical conflicts could lead to the discovery and development of novel therapeutic approaches and drug formulations.

Global Lipid Metabolism Disease Drug Market - By Distribution Channel

Based on distribution channel, the Global Lipid Metabolism Disease Drug Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The online pharmacies segment holds the highest share in the global lipid metabolism disease drug market by distribution channel. Online pharmacies offer convenient access to a wide range of medications for lipid metabolism diseases, allowing patients to order prescriptions from the comfort of their homes. The ease of online transactions, doorstep delivery, and the ability to compare prices contribute to the segment's high market share. Additionally, the growing preference for virtual consultations and the expansion of e-commerce platforms further bolster the prominence of online pharmacies in distributing lipid metabolism disease drugs globally.

Global Lipid Metabolism Disease Drug Market - By Region

The in-depth research report on The Global Lipid Metabolism Disease Drug Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Asia Pacific region dominates the global lipid metabolism disease drug market. It can be primarily due to the rising number of teenagers, leading to a higher prevalence of unhealthy lifestyles. This contributes to increased instances of obesity and heart diseases associated with elevated levels of bad cholesterol and unhealthy fats. The region's substantial demand for lipid metabolism disease drugs is a result of these prevalent health challenges, establishing the Asia Pacific as a pivotal market. Moreover, evolving dietary habits and a growing middle class population further underscore the market's importance in addressing lipid metabolism diseases in this region.

Competitive Landscape

Major players operating in the Global Lipid Metabolism Disease Drug market include: AstraZeneca Plc, Boehringer Ingelheim, Merck KGaA, Novartis AG, Takeda Pharmaceutical Co. Ltd, Eli Lilly, Johnson & Johnson, Bayer, Pfizer, and Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Lipid Metabolism Disease Drug Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Lipid Metabolism Disease Drug Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Lipid Metabolism Disease Drug Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing prevalence of lipid metabolism diseases
    • 3.2.1.2. Increasing adoption of an unhealthy lifestyle
  • 3.2.2. Restraints
    • 3.2.2.1. Side effects
    • 3.2.2.2. High costs
  • 3.2.3. Opportunities
    • 3.2.3.1. Aging population
    • 3.2.3.2. Advancements in drug development
  • 3.2.4. Challenges
    • 3.2.4.1. Regulatory hurdles
    • 3.2.4.2. Competition
• 3.3. Technological Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Lipid Metabolism Disease Drug Market Overview

• 4.1. Market Type & Forecast, 2019-2029
  • 4.1.1. By Value (USD Billion)
• 4.2. Market Share and Forecast
  • 4.2.1. By Type
    • 4.2.1.1. OTC
    • 4.2.1.2. Rx Drugs
  • 4.2.2. By Distribution Channel
    • 4.2.2.1. Hospital pharmacies
    • 4.2.2.2. Retail pharmacies
    • 4.2.2.3. Online pharmacies
  • 4.2.3. By Region
    • 4.2.3.1. North America
    • 4.2.3.2. Europe
    • 4.2.3.3. Asia Pacific (APAC)
    • 4.2.3.4. Latin America (LATAM)
    • 4.2.3.5. Middle East and Africa (MEA)

5. North America Lipid Metabolism Disease Drug Market

• 5.1. Market Type & Forecast, 2019-2029
  • 5.1.1. By Value (USD Billion)
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Country
    • 5.2.3.1. United States
    • 5.2.3.1.1. By Type
    • 5.2.3.1.2. By Distribution Channel
    • 5.2.3.2. Canada
    • 5.2.3.2.1. By Type
    • 5.2.3.2.2. By Distribution Channel

6. Europe Lipid Metabolism Disease Drug Market

• 6.1. Market Type & Forecast, 2019-2029
  • 6.1.1. By Value (USD Billion)
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
    • 6.2.3.1. Germany
    • 6.2.3.1.1. By Type
    • 6.2.3.1.2. By Distribution Channel
    • 6.2.3.2. United Kingdom
    • 6.2.3.2.1. By Type
    • 6.2.3.2.2. By Distribution Channel
    • 6.2.3.3. Italy
    • 6.2.3.3.1. By Type
    • 6.2.3.3.2. By Distribution Channel
    • 6.2.3.4. France
    • 6.2.3.4.1. By Type
    • 6.2.3.4.2. By Distribution Channel
    • 6.2.3.5. Spain
    • 6.2.3.5.1. By Type
    • 6.2.3.5.2. By Distribution Channel
    • 6.2.3.6. Belgium
    • 6.2.3.6.1. By Type
    • 6.2.3.6.2. By Distribution Channel
    • 6.2.3.7. Russia
    • 6.2.3.7.1. By Type
    • 6.2.3.7.2. By Distribution Channel
    • 6.2.3.8. The Netherlands
    • 6.2.3.8.1. By Type
    • 6.2.3.8.2. By Distribution Channel
    • 6.2.3.9. Rest of Europe
    • 6.2.3.9.1. By Type
    • 6.2.3.9.2. By Distribution Channel

7. Asia-Pacific Lipid Metabolism Disease Drug Market

• 7.1. Market Type & Forecast, 2019-2029
  • 7.1.1. By Value (USD Billion)
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
    • 7.2.3.1. China
    • 7.2.3.1.1. By Type
    • 7.2.3.1.2. By Distribution Channel
    • 7.2.3.2. India
    • 7.2.3.2.1. By Type
    • 7.2.3.2.2. By Distribution Channel
    • 7.2.3.3. Japan
    • 7.2.3.3.1. By Type
    • 7.2.3.3.2. By Distribution Channel
    • 7.2.3.4. South Korea
    • 7.2.3.4.1. By Type
    • 7.2.3.4.2. By Distribution Channel
    • 7.2.3.5. Australia & New Zealand
    • 7.2.3.5.1. By Type
    • 7.2.3.5.2. By Distribution Channel
    • 7.2.3.6. Indonesia
    • 7.2.3.6.1. By Type
    • 7.2.3.6.2. By Distribution Channel
    • 7.2.3.7. Malaysia
    • 7.2.3.7.1. By Type
    • 7.2.3.7.2. By Distribution Channel
    • 7.2.3.8. Singapore
    • 7.2.3.8.1. By Type
    • 7.2.3.8.2. By Distribution Channel
    • 7.2.3.9. Vietnam
    • 7.2.3.9.1. By Type
    • 7.2.3.9.2. By Distribution Channel
    • 7.2.3.10. Rest of APAC
    • 7.2.3.10.1. By Type
    • 7.2.3.10.2. By Distribution Channel

8. Latin America Lipid Metabolism Disease Drug Market

• 8.1. Market Type & Forecast, 2019-2029
  • 8.1.1. By Value (USD Billion)
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
    • 8.2.3.1. Brazil
    • 8.2.3.1.1. By Type
    • 8.2.3.1.2. By Distribution Channel
    • 8.2.3.2. Mexico
    • 8.2.3.2.1. By Type
    • 8.2.3.2.2. By Distribution Channel
    • 8.2.3.3. Argentina
    • 8.2.3.3.1. By Type
    • 8.2.3.3.2. By Distribution Channel
    • 8.2.3.4. Peru
    • 8.2.3.4.1. By Type
    • 8.2.3.4.2. By Distribution Channel
    • 8.2.3.5. Rest of LATAM
    • 8.2.3.5.1. By Type
    • 8.2.3.5.2. By Distribution Channel

9. Middle East and Africa Lipid Metabolism Disease Drug Market

• 9.1. Market Type & Forecast, 2019-2029
  • 9.1.1. By Value (USD Billion)
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
    • 9.2.3.1. Saudi Arabia
    • 9.2.3.1.1. By Type
    • 9.2.3.1.2. By Distribution Channel
    • 9.2.3.2. UAE
    • 9.2.3.2.1. By Type
    • 9.2.3.2.2. By Distribution Channel
    • 9.2.3.3. Qatar
    • 9.2.3.3.1. By Type
    • 9.2.3.3.2. By Distribution Channel
    • 9.2.3.4. Kuwait
    • 9.2.3.4.1. By Type
    • 9.2.3.4.2. By Distribution Channel
    • 9.2.3.5. South Africa
    • 9.2.3.5.1. By Type
    • 9.2.3.5.2. By Distribution Channel
    • 9.2.3.6. Nigeria
    • 9.2.3.6.1. By Type
    • 9.2.3.6.2. By Distribution Channel
    • 9.2.3.7. Algeria
    • 9.2.3.7.1. By Type
    • 9.2.3.7.2. By Distribution Channel
    • 9.2.3.8. Rest of MEA
    • 9.2.3.8.1. By Type
    • 9.2.3.8.2. By Distribution Channel

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Lipid Metabolism Disease Drug Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Lipid Metabolism Disease Drug Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. AstraZeneca Plc
• 12.2. Boehringer Ingelheim
• 12.3. Merck KGaA
• 12.4. Novartis AG
• 12.5. Takeda Pharmaceutical Co. Ltd
• 12.6. Eli Lilly
• 12.7. Johnson & Johnson
• 12.8. Bayer
• 12.9. Pfizer
• 12.10. Sanofi
• 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable